The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (interstitial lung disease/ILD)
Publications
Dasatinib-Related Pulmonary Toxicity Mimicking an Atypical Infection.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34(6):e46-8
Bergeron A, Réa D, Levy V, Picard C, Meignin V, Tamburini J, Bruzzoni-Giovanelli H, Calvo F, Tazi A, Rousselot P
Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.
American journal of respiratory and critical care medicine. 2007;176(8):814-8
Dasatinib-related alveolar pneumonia responsive to corticosteroids.
Leukemia & lymphoma. 2006;47(6):1180-1